GLP-1 and GLP-2 receptor co-agonist
Dapiglutide 6 mg injection once weekly
DAPIGL_SC_6MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 4.40 (0.16 to 168) | 0.26 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.62 (0.60 to 4.57) | 0.78 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.48 (0.04 to 3.93) | 0.91 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.64 (0.40 to 7.59) | 0.55 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.45 (1.09 to 24.13) | 0.24 |